# Georgiamune and Menarini Group Enter Exclusive Global License and Collaboration Agreement for GIM-621, a First-in-Class Oral Immuno-Oncology Agent

- Source: PR Newswire
- Published: 2026-10-22T14:02:00+00:00
- Category: Business
- Original: https://www.prnewswire.com/news-releases/georgiamune-and-menarini-group-enter-exclusive-global-license-and-collaboration-agreement-for-gim-621-a-first-in-class-oral-immuno-oncology-agent-302917069.html
- Canonical: https://groundlevelnews.com/story/georgiamune-and-menarini-group-enter-exclusive-global-license-and-coll-f82ae8/

GIM-621 is a preclinical-stage, first-in-class oral small molecule immunotherapy with potential application across multiple solid tumors. Georgiamune to receive $45 million in upfront and near-term payments, as part of a total deal value of up to $1.1 billion, plus royalties. FLORENCE,...

_Ground Level News shows a short summary only; the full article and all rights belong to PR Newswire._